Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. - Wikidata - wikimedia - TriplyDB

Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.

Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.

http://www.wikidata.org/entity/Q36883720

about

Linkers Having a Crucial Role in Antibody-Drug Conjugates Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and Glycans Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry Advances in Antibody Design Current Status: Site-Specific Antibody Drug Conjugates Π-Clamp-mediated cysteine conjugation Antibody-based imaging of HER-2: moving into the clinic.Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Reconstitution of Formylglycine-generating Enzyme with Copper(II) for Aldehyde Tag Conversion.Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells Chicken scFvs with an Artificial Cysteine for Site-Directed Conjugation Homogeneous antibody fragment conjugation by disulfide bridging introduces 'spinostics'.Organometallic palladium reagents for cysteine bioconjugation A self-assembling short oligonucleotide duplex suitable for pretargeting Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography.A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.Methods for site-specific drug conjugation to antibodies.Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma.Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Analytical methods for physicochemical characterization of antibody drug conjugates Antibody-drug conjugates - a perfect synergy.Designing immunoconjugates for cancer therapy.Targeted drug delivery for cancer therapy: the other side of antibodies.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.Towards the next generation of biomedicines by site-selective conjugation.Emerging site-specific bioconjugation strategies for radioimmunotracer development.A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.

P2860

Q26752763-92CA071F-F319-4EC4-8BE6-9BAFB15885A0 Q26768654-35440416-08CD-4B82-A988-46C31F76C3C1 Q28078378-9A0AE973-C2F1-4ED1-94BA-4423283809B7 Q28544658-B5133AB1-F8E4-4CAC-A606-6ABD9514C359 Q28817608-73DCE3AF-4BF9-4C10-A3D5-FED26EBD5B59 Q28829290-41B78EF4-5F03-4544-82BF-9F23E6EE0DBA Q28833204-1ECA2CBB-5E8D-44ED-883D-17B750DE9619 Q30423880-7E7CDDE7-C267-4039-89C7-DD8B89D1E46B Q33587970-E164AF0A-CF8F-4F4F-8A22-1A56B079654F Q33766408-0A2094BF-C962-4BA5-9D0D-B571C9871DC5 Q35105725-867FD77B-4B4F-4809-8C0C-AC9053011CA2 Q35459059-14741779-5FA8-40AE-914C-E2A1941A54DC Q35860701-FC9C9A0C-E3DF-47FD-AC18-854A64029E4E Q35969892-BD899C6F-168A-48B4-9A25-C8295653E9AB Q36269852-FFC94CC0-1A46-4D00-BC10-D126DA13E978 Q36463396-45D3BB14-45DE-41C6-8E38-F570A6E9AAF0 Q36708427-56AAE7ED-4ACD-47D1-9C3D-CCE78DEF20CC Q36733631-BE62AD83-72E2-4F00-A395-F8BE56D2DDCA Q37044940-4C038209-9546-4947-9116-909BF357E6EA Q37066113-2F618C52-1EC3-48DE-AE00-A1A6BCFAA2C4 Q37138223-55825CA1-BB56-4E6A-BD8F-056A56DA37CD Q37138509-C159606C-09C3-4538-85FE-77E2F6AD03C5 Q37329842-06E2B10F-76DC-470D-831F-EE61683A02B6 Q37593707-BCC8E295-1CCB-4755-871E-384FEF283504 Q37628646-55687FE1-2700-4C46-A27E-F015389E2CD1 Q37632992-132C351E-105E-47E8-9C26-1E46A21A356C Q37854644-493E9832-FDE8-4D92-8A6C-73AA90D71F9E Q37858385-4E5C638A-F226-499F-802F-67A2DC191833 Q38014923-ACB4FA00-AA94-48F6-B63B-A3064963AF80 Q38017203-E8F7A514-6236-408A-AA87-7642822B3448 Q38058816-1A52516A-0970-437E-8ECD-333A22E641FA Q38489049-1B43BB0D-B7C0-46C8-B363-362428B4C62E Q38665164-704F6DE9-FCA6-4697-9150-04C6C3A49C31 Q38706553-76BD4810-239B-4A42-B7EE-B78512E27BB8 Q38818208-099E365A-3383-4822-82A2-6653ADC11396 Q38845355-26AC0A3E-CCA9-48E2-B0F6-92DFCB2E210C Q39001270-4065EAC7-5AD3-46F0-AF9A-6C35576A2C6A Q39117341-B7F0E1C9-CF63-45F3-AB5D-A3E91B2B46F4 Q39149359-EE1E7154-BB93-4F38-9D05-619AAB63D531 Q39310345-1A5AAB17-EAF8-421E-AA6E-210733A1312E

P2860

Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.

http://www.wikidata.org/entity/Q36883720

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Reduction-alkylation strategie ...... onoclonal antibody disulfides.

@en

type

label

Reduction-alkylation strategie ...... onoclonal antibody disulfides.

@en

prefLabel

Reduction-alkylation strategie ...... onoclonal antibody disulfides.

@en

P1433

Q36883720-A531105A-298E-421C-8AC7-A74DA8A54F98

P1476

Q36883720-44B07F1A-2C44-4960-82FF-B63EA8D70DA9

P2093

Q36883720-0FB6771D-B7E5-48E9-8A15-E542F2BA3978

Q36883720-15848B54-F65C-4B6C-9F0D-4EE3EDD58FB8

Q36883720-1D6B25ED-B1E1-4522-BF43-8758F9666900

Q36883720-34B582C1-6CD4-45B0-ABCD-AE0F9D98DF4C

Q36883720-4A50D7F4-497F-4CA7-BDA5-D2B02BEFA69F

Q36883720-6585DAC1-F34F-4013-B1DE-DBA75B3CFF85

Q36883720-6DFE06E4-220C-4C05-B214-FE311AEB2C11

Q36883720-A4423B79-921F-49A8-AD16-F0F20417AED6

Q36883720-AF45AD8F-885C-494C-9BEC-4A7D8C6B5CEC

Q36883720-E26FEDD4-D52C-4732-9375-B219453640A3

P2860

Q36883720-10F572AF-8C15-4EBB-A1EB-9B7DB96A1CCA

Q36883720-1CA52564-FB32-4129-9081-44AEA8FD16AB

Q36883720-29180AEB-15C2-42F7-A27E-DF47D8D536AA

Q36883720-305D173F-7E07-42A4-B02A-90ADD5830D17

Q36883720-3FC2404B-A36A-4730-AB28-E11C176D205C

Q36883720-430DCB73-735B-422C-95A6-8A911A04EFF7

Q36883720-444DBDE0-9E0F-4736-AB28-42335DC40EBF

Q36883720-4F461754-4E2E-4137-8861-166C6354BFF9

Q36883720-55D4B020-CAED-4EEC-8764-A86085575BA8

Q36883720-58396724-D83D-40DF-BE51-08DCFE473EC5

P304

Q36883720-051D44C7-68F7-4190-83D6-505596B33A1A

P31

Q36883720-1411B7EE-B075-47F2-A13D-01A36E540C93

P356

Q36883720-624D140B-FAC4-4651-99D8-54891BD06318

P433

Q36883720-7F780940-FC60-4D73-BA4E-B5FCB7711018

P478

Q36883720-C28D9461-970A-4CDD-A1CA-100A1EA8C06A

P577

Q36883720-964D14B5-352A-4B91-BA63-0106EC2115D3

P5875

Q36883720-72D6E487-AE7A-4F98-8C51-B26F8BBC1653

P698

Q36883720-80B3AEAC-8FD7-4231-9854-F7A63EE2C93B

P921

Q36883720-5942DCB7-8C80-451B-A8A1-4DDD2849404A

P932

Q36883720-4CFF2111-C39E-4ED8-84A6-58AEF07022FD

P356

P1433

Bioconjugate Chemistry

P1476

Reduction-alkylation strategie ...... onoclonal antibody disulfides.

@en

P2093

Charles G Cerveny

http://www.w3.org/2001/XMLSchema#string

Felicia G M Handley

http://www.w3.org/2001/XMLSchema#string

Kevin J Hamblett

http://www.w3.org/2001/XMLSchema#string

Kevin S Beam

http://www.w3.org/2001/XMLSchema#string

Michael M C Sun

http://www.w3.org/2001/XMLSchema#string

Michael Y Torgov

http://www.w3.org/2001/XMLSchema#string

Nathan C Ihle

http://www.w3.org/2001/XMLSchema#string

Peter D Senter

http://www.w3.org/2001/XMLSchema#string

Richard S Blackmore

http://www.w3.org/2001/XMLSchema#string

Stephen C Alley

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

Refined structure of an intact IgG2a monoclonal antibody

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

Monoclonal antibody drug immunoconjugates for targeted treatment of cancer.

Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations.

Radioimmunoimaging. Advances and prospects.

Perspectives on cancer therapy with radiolabeled monoclonal antibodies.

Enzyme immunoassay techniques. An overview.

DISSOCIATION OF RABBIT GAMMA GLOBULIN INTO SUBUNITS BY REDUCTION AND ACIDIFICATION.

P304

1282-1290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/BC050201Y

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7589721

http://www.w3.org/2001/XMLSchema#string

P698

16173809

http://www.w3.org/2001/XMLSchema#string

P921

P932

2539111

http://www.w3.org/2001/XMLSchema#string